Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Zhongyu Yuan"'
Autor:
Yanxia Shi, Ying Lin, Kuikui Jiang, Xin An, Heng Huang, Jian-Li Zhao, Zhongyu Yuan, Xiwen Bi, Wen Xia, Lehong Zhang, Zhiyong Wu, Fei Xu, Xin Hua, Ruoxi Hong, Ying Guo, Cong Xue, Yong-Yi Zhong, Yuan-Qi Zhang, An-Qing Zhang, Xin-Mei Liu, Jia Jia Huang, Shusen Wang
Publikováno v:
Clinical Cancer Research. 28:637-645
Purpose: There is no research evidence demonstrate which is the better partner strategy, endocrine therapy or chemotherapy, to combine with anti-HER2 therapy as the first-line management of hormone receptor (HR)-positive (HR+) and HER2-positive (HER2
Publikováno v:
JAMA. 325(17)
Autor:
Zhangzan Huang, Wei Shi, Xinyue Wang, Jia Jia Huang, Zhongyu Yuan, Xiwen Bi, Yanhong Su, Wen Xia
Publikováno v:
Journal of Cancer Therapy. 10:146-156
Purpose: Endocrine therapy is one of the main treatment options for hormone receptor (HR)-positive advanced breast cancer (ABC). However, whether the combination of endocrine therapy with chemotherapy is practicable and more effective than endocrine
Autor:
Heng Huang, Xin An, Kuikui Jiang, Zhongyu Yuan, Fei Xu, Wen Xia, Shusen Wang, Yanxia Shi, Lehong Zhang, Xi Wang, Xin Hua, Cong Xue, Li Cai, Qian-Jun Chen, Jun Tang, Ruoxi Hong, Wang-Zhong Li, Xiwen Bi, Jia Jia Huang, Ying Lin
Publikováno v:
Journal of Clinical Oncology. 39:521-521
521 Background: Recent clinical trials and meta-analysis have suggested the benefit of adding capecitabine to standard chemotherapy in early-stage triple negative breast cancer (TNBC). We aimed to develop an individualized prediction model to quantif
Autor:
Huiping Li, Yongmei Yin, Xiao Jia Wang, Zhongyu Yuan, Cuizhi Geng, Pin Zhang, Xichun Hu, Yongsheng Wang, Jing Cheng, Binghe Xu, Rou-Jun Peng, Zefei Jiang, Qingyuan Zhang, Jian Liu, Baochun Zhang, Zhongsheng Tong, Shude Cui, Shaohua Zhang, Hongming Pan, Hong Zheng, Li Tang, Tao Sun, Yuee Teng, Qiang Yao, Jian Huang, Min Yan, Jinsong Lu, Rongguo Qiu, Junlan Yang, Ping Sun
Publikováno v:
The Lancet Oncology. 18:371-383
Utidelone, a genetically engineered epothilone analogue, has shown promise as a potential treatment for breast cancer in phase 1 and 2 trials. The aim of this phase 3 trial was to compare the efficacy and safety of utidelone plus capecitabine versus
Autor:
Jian Zeng, Yanxia Shi, Shusen Wang, Xin-Mei Liu, Jun Tang, Li Zhao, Lehong Zhang, Jia Jia Huang, Zhongyu Yuan, Xi Wang, Xianming Wang, Yong-Li Ke, Qian-Jun Chen, Danmei Pang, Heng Huang, Roujun Peng, Ying Lin, Fei Xu, Li Cai, Anqin Zhang
Publikováno v:
Journal of Clinical Oncology. 38:507-507
507 Background: Triple-negative breast cancer (TNBC) has a relatively high relapse rate and poor outcome after standard therapy among all subtypes of breast cancer. Effective strategies to reduce risk of relapse and death are unmet medical needs. Met
Autor:
Yuee Teng, Zhongyu Yuan, Zefei Jiang, Huiping Li, Shude Cui, Yongsheng Wang, Binghe Xu, Xichun Hu, Xiaojia Wang, Pin Zhang, Hongming Pan, Qiang Yao, Junlan Yang, Zhongsheng Tong, Qingyuan Zhang, Tao Sun
Publikováno v:
Journal of Clinical Oncology. 36:1003-1003
1003Background: Utidelone, a genetically engineered epothilone analog, showed excellent efficacy in phase II and III trials in terms of PFS as a primary end point and ORR as a secondary end point. ...
Autor:
Shude Cui, Pin Zhang, Tao Sun, Yuee Teng, Zefei Jiang, Qingyuan Zhang, Wang Xiao Jia, Xichun Hu, Binghe Xu, Zhongyu Yuan
Publikováno v:
Journal of Clinical Oncology. 34:1004-1004
1004Background: Utidelone, a genetically engineered epothilone analog, is a microtubule stabilizing agent that showed promising activities in phase I and phase II trials. In this report, a multi-ce...